Date: March 11, 2025Renowned Cancer Researcher Honored in 2025The American Association for Cancer Research (AACR) and the Pezcoller Foundation proudly…
Browsing: AACR
LOS ANGELES AACR IO 2025At a recent oncology session from AACR Immunotherapy 2025, Melissa G. Lechner, MD, PhD, presented findings…
Posted on February 28, 2025 | Jose Ramon Conejo-Garcia,MD, PHD – Duke Cancer InstituteCancer immunotherapy has long been dominated by…
February 26, 2025 | By Michael Karin, PhdLiver cancer, specifically hepatocellular carcinoma (HCC), is on the rise—and a sneaky culprit…
Los Angeles, February 2025 The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research.…
Los Angeles, February 2025 – The inaugural AACR IO Conference kicked off with an electrifying start, bringing together the world’s…
“So basically, we looked at two factors, the one saying the long term remission of heart positive metastatic breast cancer…
Dr. Charles Link recently discussed the innovative SYNC-T technology (Syncromune® Inc.) during a phase one trial targeting hormone-refractory prostate cancer—a…
…The field of oncology is continuously evolving, with research focusing on developing more effective and personalized treatment modalities. One such…
…Pancreatic cancer, notorious for its lethality and late-stage diagnosis, presents significant challenges in oncological treatment and patient survival. Dr. Ajay…
…IntroductionSmall cell lung cancer (SCLC) is notoriously aggressive and challenging to treat, with current therapies often providing limited benefit due…
By. Tyler Ames, PhDDate. November 01, 2023Tyler Ames, Ph.D. in oncology research, delves into the intricate mechanisms of PT-112’s impact…
Ethnic Minorities: Empowering to Increase Colorectal Cancer Screening Through Community Outreach Kimlin Ashing PhD By Kimlin Tam Ashing, PhDProfessor, Department…
CAR T-cell: Advances in Adoptive Therapies for Targeting Heterogeneity in mCRPC Lupita Lopez By Lupita Lopez, BS Ph.D. candidate at…
Diabetes Cancer: Racial Disparities In Prevention An Epidemiological Perspective By Gaole Song By Gaole Song, DrPH From the City of…
Tafasitamab: Final Results of Five-Year Safety and Efficacy Study (Phase II L-MIND) Prof. Kalakonda By Professor Nagesh Kalakonda Thank you…
CD70: How Does ALLO-316 Eliminate or Destroy Malignancies in the TRAVERSE Trial? Samer Srour, MB ChB, MS By Samer Srour,…